- Home
- CGEM
as 12-23-2024 4:00pm EST
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 730.2M | IPO Year: | 2021 |
| Target Price: | $31.67 | AVG Volume (30 days): | 514.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.24 - $30.19 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Cullinan Oncology Inc. (CGEM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Jones Jeffrey Alan | CGEM | Chief Medical Officer | Dec 18 '24 | Sell | $11.41 | 4,632 | $52,851.12 | 114,059 | |
| SUMER JACQUELYN L | CGEM | Chief Legal Officer | Dec 18 '24 | Sell | $11.41 | 3,482 | $39,729.62 | 90,651 | |
| Michaelson Jennifer | CGEM | Chief Scientific Officer | Dec 18 '24 | Sell | $11.41 | 4,693 | $53,547.13 | 99,760 | |
| Michaelson Jennifer | CGEM | Chief Scientific Officer | Dec 12 '24 | Sell | $12.52 | 3,489 | $43,682.28 | 99,760 | |
| Michaelson Jennifer | CGEM | Chief Scientific Officer | Nov 5 '24 | Sell | $15.64 | 8,000 | $125,120.00 | 99,760 |
Latest Cullinan Oncology Inc. News
CGEM Breaking Stock News: Dive into CGEM Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
GlobeNewswire
2 months ago
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire
2 months ago
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
GlobeNewswire
2 months ago
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
GlobeNewswire
2 months ago
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
GlobeNewswire
3 months ago
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
GlobeNewswire
3 months ago
Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus
GlobeNewswire
3 months ago
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
Compare CGEM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CGEM Cullinan Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.